Targovax ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more
Targovax ASA (0RIS) - Total Liabilities
Latest total liabilities as of June 2021: Nkr138.59 Million NOK
Based on the latest financial reports, Targovax ASA (0RIS) has total liabilities worth Nkr138.59 Million NOK as of June 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Targovax ASA - Total Liabilities Trend (2017–2020)
This chart illustrates how Targovax ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Targovax ASA Competitors by Total Liabilities
The table below lists competitors of Targovax ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pacific Online Limited
PINK:PCOLF
|
USA | $229.88 Million |
|
D3 Energy Ltd
AU:D3E
|
Australia | AU$237.81K |
|
Enzo Biochem Inc
NYSE:ENZ
|
USA | $20.12 Million |
|
PT TBS Energi Utama Tbk
F:6AU
|
Germany | €563.55 Million |
|
MMP Industries Limited
NSE:MMP
|
India | ₹2.42 Billion |
|
Yjn Co.,Ltd.
TWO:3191
|
Taiwan | NT$105.29 Million |
|
OY Nofar Energy Ltd
TA:NOFR
|
Israel | ILA5.45 Billion |
|
Concord Medical Services Holdings
NYSE:CCM
|
USA | $5.01 Billion |
Liability Composition Analysis (2017–2020)
This chart breaks down Targovax ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Targovax ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Targovax ASA (2017–2020)
The table below shows the annual total liabilities of Targovax ASA from 2017 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-12-31 | Nkr148.15 Million | -7.38% |
| 2019-12-31 | Nkr159.95 Million | -1.83% |
| 2018-12-31 | Nkr162.94 Million | +19.41% |
| 2017-12-31 | Nkr136.45 Million | -- |